
Lessons from scaling up access to ART and foreseen challenges with long-acting technologies

Rajesh Murthy

Medicines Patent Pool

About the Medicines Patent Pool

Founded in 2010, The Medicines Patent Pool (MPP) is a United Nations-backed public health organization with a mission to increase equitable access to innovative, quality-assured essential medicines and health technologies for low- and middle-income countries through public health-oriented voluntary licensing and technology transfer.

Having successfully implemented our voluntary licensing model in the **infectious diseases'** areas, in the past three years we further expanded our activities to cover:

- patented **essential medicines** included in the WHO Essential Medicines List (EML) and those with **strong potential** for future inclusion;
- any health technology that could contribute to the global response to **COVID-19, including tech transfer support**

MPP's mandate covers:

Infectious Diseases*

*HIV
Viral Hepatitis
TB*

Non-communicable diseases (NCDs)*


E.g., cancer, type-2 diabetes, etc.

COVID-19*

Tech Transfer

Long-acting technologies

Funders:




*Products on the WHO Essential Medicines List (EML) and products with potential for future inclusion

The MPP Model and Effective PLHIV coverage in LMICs

Countries in which MPP's licensed products for HIV are accessible

130 countries
>99% coverage



Help identify treatment needs



People living
in LMICs

MPP Impact* - Uptake, Economic, Health and Key Takeaways

15 patent holders signed agreements with MPP

55 generic manufacturers have sublicenses from MPP



26.91 Bn doses of treatment supplied (2010-2021)



US\$1.2 Bn dollars saved through MPP's licences (2010-2021)



By 2030
US\$ 3.5 Bn
projected savings

148 countries have benefited from access to MPP-licensed products




71.76 Mn patient-years of treatment through MPP's generic partners (2010-2021)



18,000 deaths averted (2010-2021)



By 2030
160,000
projected deaths averted



A detailed presentation of the impact methodology and results to be presented at AIDS 2022

AIDS 2022 session OAE04
Achieving sustainability in the HIV response: Thinking differently!
Tuesday, 2 August 10:30 / Room 516 - Channel 6
Abstract OAE0403 to be presented by Sébastien Morin

Long-Acting Technologies for HCV, TB, and Malaria



In Sep 2021, the Medicines Patent Pool signed a licence agreement with **Tandem Nano Ltd.** for **UoL's Unitaid-funded project LONGEVITY long-acting technologies**, which, if proven safe and effective could help achieve optimal dosing regimens for **malaria chemoprophylaxis, tuberculosis prevention, and hepatitis C cure**



LA PaL
THE LONG-ACTING TECHNOLOGIES
PATENTS AND LICENCES DATABASE

A new collaborative tool supporting access to innovation in the long-acting space

What is LAPaL ?

LAPaL is a compilation of **technical and intellectual property** information on long-acting technologies and their potential applications.

It aims to facilitate collaborations and advocate for **access**, in particular for users in **low- and middle-income countries**.

Long-acting injectable HIV drug combination technology



In Dec 2021, the Medicines Patent Pool and the **University of Washington** signed a licence agreement on a **long-acting injectable (LAI) drug combination candidate – TLD**, that is being developed for use in **HIV treatment (SC monthly injection)**, with support from Unitaid. This LAI candidate, if proven safe, effective, and acceptable, could contribute to reducing pill burden significantly

Long-Acting injectable for HIV PrEP – **under negotiations**



In May 2022, **ViiV Healthcare** committed to grant VL for patents relating to **Cabotegravir Long-Acting for PrEP** to Medicines Patent Pool. ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative **HIV prevention measure**